Better Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer
Pfizer | January 07, 2017
Last year a handful of setbacks led shares of Regeneron Pharmaceuticals (NASDAQ:REGN) about 29% lower, while Pfizer (NYSE:PFE) stock ended 2016 about 2% higher than it began. Sales of Regeneron's lead product have been tapering off, but a handful of potential blockbusters could provide some big gains in 2017 and beyond. The pharma giant, meanwhile, also has some exciting growth drivers in its lineup, but an aging product line will make big gains difficult going forward.